Skip to Content
Merck
CN
  • The effects of low level laser therapy on both HIV-1 infected and uninfected TZM-bl cells.

The effects of low level laser therapy on both HIV-1 infected and uninfected TZM-bl cells.

Journal of biophotonics (2017-01-28)
Masixole Yvonne Lugongolo, Sello Lebohang Manoto, Saturnin Ombinda-Lemboumba, Malik Maaza, Patience Mthunzi-Kufa
ABSTRACT

Human immunodeficiency virus (HIV-1) infection remains a major health problem despite the use of highly active antiretroviral therapy (HAART), which has greatly reduced mortality rates. Due to the unavailability of an effective vaccine and treatment that would completely eradicate the virus in infected individuals, the quest for new therapies continues. Low level laser therapy (LLLT) involves the exposure of cells to low levels of red or infrared light. LLLT has been widely used in different medical conditions, but not in HIV-1 infection. This study aimed to determine the effects of LLLT on HIV-1 infected and uninfected TZM-bl cells. Both infected and uninfected cells were irradiated at a wavelength of 660 nm with different fluences from 2 J/cm

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dulbecco′s Modified Eagle′s Medium - high glucose, With 4500 mg/L glucose, L-glutamine, and sodium bicarbonate, without sodium pyruvate, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Trypsin-EDTA solution, 0.25%, sterile-filtered, BioReagent, suitable for cell culture, 2.5 g porcine trypsin and 0.2 g EDTA, 4Na per liter of Hanks′ Balanced Salt Solution with phenol red
Sigma-Aldrich
L-Glutamine–Penicillin–Streptomycin solution, L-glutamine 200 mM, streptomycin 10 mg/mL, penicillin 10,000 units, 0.1 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
DEAE-Dextran hydrochloride, powder